Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Aug;31(8):1225–1230. doi: 10.1128/aac.31.8.1225

Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

F Kawana, S Shigeta, M Hosoya, H Suzuki, E De Clercq
PMCID: PMC174908  PMID: 3307618

Abstract

We examined the inhibitory effect of 20 antiviral compounds, including ribavirin, on the replication of respiratory syncytial virus in HeLa and HEp-2 cell cultures. Of the compounds studied, pyrazofurin and 3-deazaguanine emerged as more potent inhibitors of respiratory syncytial virus than ribavirin. Based on their inhibitory effect on the cytopathogenicity of respiratory syncytial virus in HeLa cells, the average 50% effective dose of pyrazofurin and 3-deazaguanine for eight strains was 0.07 and 1.65 micrograms/ml, respectively; that of ribavirin was 5.82 micrograms/ml. The cytotoxicity of these compounds for HeLa cells was examined by monitoring the incorporation of radiolabeled uridine into cellular RNA. The selectivity indexes of pyrazofurin and 3-deazaguanine exceeded that of ribavirin by 70- and 11-fold, respectively. Pyrazofurin, 3-deazaguanine, and ribavirin inhibited both viral antigen expression and syncytium formation in HeLa cell cultures, as assessed by an indirect immunofluorescence assay. In these assays, pyrazofurin and 3-deazaguanine again proved more potent than ribavirin. 2,5-Diamidinoindole and carbodine were less potent than ribavirin. Various other compounds, i.e., 3-adenin-9-yl-2-hydroxypropanoic acid isobutyl ester, 3-deazauridine, 3'-C-methyluridine, 5'-deoxy-5-fluorouridine, 5-cyanoimidazole-4-carboxamide, and its ribofuranosyl derivative, did not inhibit the cytopathic effect of the Long strain of respiratory syncytial virus at concentrations greater than or equal to 125 micrograms/ml. Tubercidin, 5-chlorotubercidin, xylotubercidin, neplanocin A, thiosemicarbazone R, and 3-methylquercetine were too toxic to HeLa cells for their inhibitory effects on respiratory syncytial virus to be examined.

Full text

PDF
1225

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. B., Huffman J. H., Dan Cook P., Meyer R. B., Jr, Robins R. K., Sidwell R. W. Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid. Antimicrob Agents Chemother. 1977 Jul;12(1):114–119. doi: 10.1128/aac.12.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergstrom D. E., Brattesani A. J., Ogawa M. K., Reddy P. A., Schweickert M. J., Balzarini J., De Clercq E. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem. 1984 Mar;27(3):285–292. doi: 10.1021/jm00369a010. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother. 1985 Jul;28(1):84–89. doi: 10.1128/aac.28.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De Clercq E., Bernaerts R., Bergstrom D. E., Robins M. J., Montgomery J. A., Holy A. Antirhinovirus activity of purine nucleoside analogs. Antimicrob Agents Chemother. 1986 Mar;29(3):482–487. doi: 10.1128/aac.29.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Clercq E., Holý A. Alkyl esters of 3-adenin-9-yl-2-hydroxypropanoic acid: a new class of broad-spectrum antiviral agents. J Med Chem. 1985 Mar;28(3):282–287. doi: 10.1021/jm00381a004. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2;323(6087):464–467. doi: 10.1038/323464a0. [DOI] [PubMed] [Google Scholar]
  7. Dubovi E. J., Geratz J. D., Shaver S. R., Tidwell R. R. Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob Agents Chemother. 1981 Apr;19(4):649–656. doi: 10.1128/aac.19.4.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dubovi E. J., Geratz J. D., Tidwell R. R. Inhibition of respiratory syncytial virus by bis(5-amidino-2-benzimidazolyl)methane. Virology. 1980 Jun;103(2):502–509. doi: 10.1016/0042-6822(80)90207-x. [DOI] [PubMed] [Google Scholar]
  9. Gladych J. M., Hunt J. H., Jack D., Haff R. F., Boyle J. J., Stewart R. C., Ferlauto R. J. Inhibition of rhinovirus by isatin thiosemicarbazone analogues. Nature. 1969 Jan 18;221(5177):286–287. doi: 10.1038/221286b0. [DOI] [PubMed] [Google Scholar]
  10. Goswami B. B., Borek E., Sharma O. K., Fujitaki J., Smith R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun. 1979 Aug 13;89(3):830–836. doi: 10.1016/0006-291x(79)91853-9. [DOI] [PubMed] [Google Scholar]
  11. Gutowski G. E., Sweeney M. J., DeLong D. C., Hamill R. L., Gerzon K., Dyke R. W. Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial. Ann N Y Acad Sci. 1975 Aug 8;255:544–551. doi: 10.1111/j.1749-6632.1975.tb29257.x. [DOI] [PubMed] [Google Scholar]
  12. Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  13. Hall C. B., Walsh E. E., Hruska J. F., Betts R. F., Hall W. J. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA. 1983 May 20;249(19):2666–2670. [PubMed] [Google Scholar]
  14. Henderson F. W., Clyde W. A., Jr, Collier A. M., Denny F. W., Senior R. J., Sheaffer C. I., Conley W. G., 3rd, Christian R. M. The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice. J Pediatr. 1979 Aug;95(2):183–190. doi: 10.1016/s0022-3476(79)80647-2. [DOI] [PubMed] [Google Scholar]
  15. Horn M. E., Brain E., Gregg I., Yealland S. J., Inglis J. M. Respiratory viral infection in childhood. A survey in general practice, Roehampton 1967-1972. J Hyg (Lond) 1975 Apr;74(2):157–168. doi: 10.1017/s0022172400024220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hruska J. F., Bernstein J. M., Douglas R. G., Jr, Hall C. B. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother. 1980 May;17(5):770–775. doi: 10.1128/aac.17.5.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hruska J. F., Morrow P. E., Suffin S. C., Douglas R. G., Jr In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother. 1982 Jan;21(1):125–130. doi: 10.1128/aac.21.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. KISCH A. L., JOHNSON K. M., CHANOCK R. M. Immunofluorescence with respiratory syncytial virus. Virology. 1962 Feb;16:177–189. doi: 10.1016/0042-6822(62)90293-3. [DOI] [PubMed] [Google Scholar]
  20. Kim H. W., Arrobio J. O., Brandt C. D., Jeffries B. C., Pyles G., Reid J. L., Chanock R. M., Parrott R. H. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol. 1973 Sep;98(3):216–225. doi: 10.1093/oxfordjournals.aje.a121550. [DOI] [PubMed] [Google Scholar]
  21. Kim H. W., Leikin S. L., Arrobio J., Brandt C. D., Chanock R. M., Parrott R. H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976 Jan;10(1):75–78. doi: 10.1203/00006450-197601000-00015. [DOI] [PubMed] [Google Scholar]
  22. McClung H. W., Knight V., Gilbert B. E., Wilson S. Z., Quarles J. M., Divine G. W. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983 May 20;249(19):2671–2674. [PubMed] [Google Scholar]
  23. McIntosh K., Kurachek S. C., Cairns L. M., Burns J. C., Goodspeed B. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child. 1984 Mar;138(3):305–308. doi: 10.1001/archpedi.1984.02140410083024. [DOI] [PubMed] [Google Scholar]
  24. Prince G. A., Jenson A. B., Horswood R. L., Camargo E., Chanock R. M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol. 1978 Dec;93(3):771–791. [PMC free article] [PubMed] [Google Scholar]
  25. Rombaut B., Vrijsen R., Boeye A. Comparison of arildone and 3-methylquercetin as stabilizers of poliovirus. Antiviral Res. 1985;Suppl 1:67–73. doi: 10.1016/s0166-3542(85)80010-3. [DOI] [PubMed] [Google Scholar]
  26. Schieble J. H., Kase A., Lennette E. H. Fluorescent cell counting as an assay method for respiratory syncytial virus. J Virol. 1967 Jun;1(3):494–499. doi: 10.1128/jvi.1.3.494-499.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shannon W. M., Arnett G., Westbrook L., Shealy Y. F., O'Dell C. A., Brockman R. W. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob Agents Chemother. 1981 Dec;20(6):769–776. doi: 10.1128/aac.20.6.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Shigeta S., Hinuma Y., Suto T., Ishida N. The cell to cell infection of respiratory syncytial virus in HEp-2 monolayer cultures. J Gen Virol. 1968 Jul;3(1):129–131. doi: 10.1099/0022-1317-3-1-129. [DOI] [PubMed] [Google Scholar]
  29. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  30. Stott E. J., Taylor G. Respiratory syncytial virus. Brief review. Arch Virol. 1985;84(1-2):1–52. doi: 10.1007/BF01310552. [DOI] [PubMed] [Google Scholar]
  31. Streeter D. G., Koyama H. H. Inhibition of purine nucleotide biosynthesis by 3-deazaguanine, its nucleoside and 5'-nucleotide. Biochem Pharmacol. 1976 Nov 1;25(21):2413–2415. doi: 10.1016/0006-2952(76)90041-1. [DOI] [PubMed] [Google Scholar]
  32. Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Suto T., Yano N., Ikeda M., Miyamoto M., Takai S., Shigeta S., Hinuma Y., Ishida N. Respiratory syncytial virus infection and its serologic epidemiology. Am J Epidemiol. 1965 Nov;82(3):211–224. doi: 10.1093/oxfordjournals.aje.a120545. [DOI] [PubMed] [Google Scholar]
  34. Taber L. H., Knight V., Gilbert B. E., McClung H. W., Wilson S. Z., Norton H. J., Thurson J. M., Gordon W. H., Atmar R. L., Schlaudt W. R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov;72(5):613–618. [PubMed] [Google Scholar]
  35. Taylor G., Stott E. J., Hughes M., Collins A. P. Respiratory syncytial virus infection in mice. Infect Immun. 1984 Feb;43(2):649–655. doi: 10.1128/iai.43.2.649-655.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tidwell R. R., Geratz J. D., Clyde W. A., Jr, Rosenthal K. U., Dubovi E. J. Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane. Antimicrob Agents Chemother. 1984 Oct;26(4):591–593. doi: 10.1128/aac.26.4.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tolman R. L., Field A. K., Karkas J. D., Wagner A. F., Germershausen J., Crumpacker C., Scolnick E. M. 2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity. Biochem Biophys Res Commun. 1985 May 16;128(3):1329–1335. doi: 10.1016/0006-291x(85)91086-1. [DOI] [PubMed] [Google Scholar]
  38. Wyde P. R., Sun C. S., Knight V. Replication of respiratory syncytial virus in lungs of immunodeficient mice. J Reticuloendothel Soc. 1983 Aug;34(2):125–129. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES